Track topics on Twitter Track topics that are important to you
Monthly lampalizumab, a potential therapy for patients with geographic atrophy secondary to age-related macular degeneration, reduced lesion area progression by 20% compared to a sham control, according to results of the MAHALO study. The phase 2 clinical trial, a multicenter, randomized controlled study, included patients with geographic atrophy secondary to age-related macular degeneration randomized into three treatment groups: 42 patients receiving 10 mg intravitreal injections of lampalizumab every month, 41 patients receiving injections every other month and 40 patients in a sham control group.
Original Article: Lampalizumab reduces geographic atrophy lesion progressionNEXT ARTICLE
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...